Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986484 Monotherapy and Combination Therapy in Advanced Solid Malignancies
NCT06544655Phase 1Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1 trial of BMS-986484 in solid tumor, non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and 4 more (8 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 3 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
BMS-986484
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06544655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544655.